Trials / Completed
CompletedNCT00568334
Study of Two Formulations of GSK Biologicals' Varicella Vaccine
Study of Two Formulations of GSK Biologicals' Varicella Vaccine Given as a 2-dose Course in the Second Year of Life
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 244 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 11 Months – 21 Months
- Healthy volunteers
- Accepted
Summary
The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety. This present study is undertaken to rule out any negative impact on the immunogenicity and safety of GSK Biologicals' live attenuated varicella virus vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Varilrix (inactivated varicella vaccine) | subcutaneously injection |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-03-18
- Completion
- 2008-04-29
- First posted
- 2007-12-06
- Last updated
- 2018-06-08
- Results posted
- 2017-06-28
Locations
13 sites across 2 countries: Czechia, Hungary
Source: ClinicalTrials.gov record NCT00568334. Inclusion in this directory is not an endorsement.